Fig. 3
From: The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-β peptide
Treatment of neuroblastoma cells with recombinant ANXA1 does not affect BACE1 activity or expression. a Representative Western blots and quantification of β-CTF expression in N2asw cells treated with 2–4 μg/ml hrANXA1 for 18 h (n = 9–18 samples) or transfected with control or ANXA1 siRNA (n = 9 samples) and normalised to full-length APP. b Representative Western blots and quantification of BACE1 protein expression in N2asw cells treated with 2–4 μg/ml hrANXA1 for 18 h and normalised to GAPDH (n = 6–12 samples). c Representative Western blots and quantification of BACE1 protein expression in SK-N-SH cells treated with 0.5–2 μg/ml hrANXA1 for 18 h and normalised to GAPDH (n = 15–27 samples). d Quantification of BACE1 mRNA expression by qPCR analysis in SK-N-SH cells treated with 2 μg/ml hrANXA1 for 18 h (n = 9 samples). e Quantification of β-secretase activity in N2asw cells following treatment with 4 μg/ml hrANXA1 for 18 h (n = 5 samples). Values shown in graphs represent the mean value ± SEM and are expressed as fold change in comparison to the normalized control